Literature DB >> 21768280

Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.

Deborah H Schmiel1, Elizabeth E Moran, Paul B Keiser, Brenda L Brandt, Wendell D Zollinger.   

Abstract

Analysis of the specificity of bactericidal antibodies in normal, convalescent, and postvaccination human sera is important in understanding human immunity to meningococcal infections and can aid in the design of an effective group B vaccine. A collection of human sera, including group C and group B convalescent-phase sera, normal sera with naturally occurring cross-reactive bactericidal activity, and some postvaccination sera, was analyzed to determine the specificity of cross-reactive bactericidal antibodies. Analysis of human sera using a bactericidal antibody depletion assay demonstrated that a significant portion of the bactericidal activity could be removed by purified lipopolysaccharide (LPS). LPS homologous to that expressed on the bactericidal test strain was most effective, but partial depletion by heterologous LPS suggested the presence of antibodies with various degrees of cross-reactivity. Binding of anti-L3,7 LPS bactericidal antibodies was affected by modification of the core structure, suggesting that these functional antibodies recognized epitopes consisting of both core structures and lacto-N-neotetraose (LNnT). When the target strain was grown with 5'-cytidinemonophospho-N-acetylneuraminic acid (CMP-NANA) to increase LPS sialylation, convalescent-phase serum bactericidal titers were decreased by only 2- to 4-fold, and most remaining bactericidal activity was still depleted by LPS. Highly sialylated LPS was ineffective in depleting bactericidal antibodies. We conclude that natural infections caused by strains expressing L3,7 LPS induce persistent, protective bactericidal antibodies and appear to be directed against nonsialylated bacterial epitopes. Additionally, subsets of these bactericidal antibodies are cross-reactive, binding to several different LPS immunotypes, which is a useful characteristic for an effective group B meningococcal vaccine antigen.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21768280      PMCID: PMC3187254          DOI: 10.1128/IAI.05125-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  61 in total

1.  Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers.

Authors:  J J Drabick; B L Brandt; E E Moran; N B Saunders; D R Shoemaker; W D Zollinger
Journal:  Vaccine       Date:  1999-08-20       Impact factor: 3.641

2.  Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.

Authors:  J W Tappero; R Lagos; A M Ballesteros; B Plikaytis; D Williams; J Dykes; L L Gheesling; G M Carlone; E A Høiby; J Holst; H Nøkleby; E Rosenqvist; G Sierra; C Campa; F Sotolongo; J Vega; J Garcia; P Herrera; J T Poolman; B A Perkins
Journal:  JAMA       Date:  1999-04-28       Impact factor: 56.272

Review 3.  Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion.

Authors:  Nicole Baumgarth; James W Tung; Leonore A Herzenberg
Journal:  Springer Semin Immunopathol       Date:  2005-01-05

4.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

5.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

6.  Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits.

Authors:  A D Cox; W Zou; M A J Gidney; S Lacelle; J S Plested; K Makepeace; J C Wright; P A Coull; E R Moxon; J C Richards
Journal:  Vaccine       Date:  2005-10-17       Impact factor: 3.641

7.  Carbohydrate composition of meningococcal lipopolysaccharide modulates the interaction of Neisseria meningitidis with human dendritic cells.

Authors:  Oliver Kurzai; Corinna Schmitt; Heike Claus; Ulrich Vogel; Matthias Frosch; Annette Kolb-Mäurer
Journal:  Cell Microbiol       Date:  2005-09       Impact factor: 3.715

8.  Inner core assembly and structure of the lipooligosaccharide of Neisseria meningitidis: capacity of strain NMB to express all known immunotype epitopes.

Authors:  Charlene M Kahler; Anup Datta; Yih-ling Tzeng; Russell W Carlson; David S Stephens
Journal:  Glycobiology       Date:  2004-12-01       Impact factor: 4.313

Review 9.  Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin).

Authors:  C M Kahler; D S Stephens
Journal:  Crit Rev Microbiol       Date:  1998       Impact factor: 7.624

10.  The lipooligosaccharide (LOS) of Neisseria meningitidis serogroup B strain NMB contains L2, L3, and novel oligosaccharides, and lacks the lipid-A 4'-phosphate substituent.

Authors:  M M Rahman; D S Stephens; C M Kahler; J Glushka; R W Carlson
Journal:  Carbohydr Res       Date:  1998-02       Impact factor: 2.104

View more
  6 in total

1.  Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated transferrin-binding protein B in liposomes: implications for vaccine development.

Authors:  Noëlle Mistretta; Bruno Guy; Yves Bérard; François Dalençon; Olivia Fratantonio; Christophe Grégoire; Aurélie Lechevallier; Philippe Lhéritier; Laurent Revet; Monique Moreau; Jean Haensler; Bachra Rokbi
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

2.  Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: conjugates based on core oligosaccharides.

Authors:  F St Michael; C M Cairns; A L Filion; A Biolchi; B Brunelli; M Giuliani; J C Richards; A D Cox
Journal:  Glycoconj J       Date:  2013-09-07       Impact factor: 2.916

3.  The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C.

Authors:  Elizabeth Partridge; Eduardo Lujan; Serena Giuntini; David M Vu; Dan M Granoff
Journal:  Vaccine       Date:  2017-06-23       Impact factor: 3.641

4.  Opc expression, LPS immunotype switch and pilin conversion contribute to serum resistance of unencapsulated meningococci.

Authors:  Kerstin Hubert; Marie-Christin Pawlik; Heike Claus; Hanna Jarva; Seppo Meri; Ulrich Vogel
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

5.  Effect of fresh frozen plasma on the in vitro activation of U937 monocytes: a potential role for the age of blood donors and their underlying cytokine profile.

Authors:  Mariana Patlán; Fausto Sánchez-Muñoz; Luis M Amezcua-Guerra; Adriana Granados; Araceli Páez; Felipe Massó; Ana M Mejía; Angeles Soster; Rafael Bojalil; Lenin Pavón; Luis A Jiménez-Zamudio; Ricardo Márquez-Velasco
Journal:  Biol Res       Date:  2017-12-21       Impact factor: 5.612

Review 6.  Recent Progress in the Prevention of Serogroup B Meningococcal Disease.

Authors:  Ian M Feavers; Martin C J Maiden
Journal:  Clin Vaccine Immunol       Date:  2017-05-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.